Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
36
ABEO Quote, Financials, Valuation and Earnings
Last price:
$4.87
Seasonality move
:
24.66%
Day range:
$4.69 - $4.92
52-week range:
$3.93 - $7.54
Dividend yield:
0%
P/E ratio:
4.18x
P/S ratio:
658.38x
P/B ratio:
1.54x
Volume:
954.9K
Avg. volume:
2.4M
1-year change:
-18.97%
Market cap:
$263.9M
Revenue:
--
EPS (TTM):
$1.17
Analysts' Opinion
-
Consensus RatingAbeona Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.64, Abeona Therapeutics, Inc. has an estimated upside of 323.88% from its current price of $4.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $4.87.
Fair Value
-
According to the consensus of 6 analysts, Abeona Therapeutics, Inc. has 323.88% upside to fair value with a price target of $20.64 per share.
ABEO vs. S&P 500
-
Over the past 5 trading days, Abeona Therapeutics, Inc. has underperformed the S&P 500 by -5.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Abeona Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Abeona Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Abeona Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Abeona Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Abeona Therapeutics, Inc. reported earnings per share of -$0.10.
Enterprise value:
80.6M
EV / Invested capital:
0.41x
Price / LTM sales:
658.38x
EV / EBIT:
--
EV / Revenue:
201.41x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.98x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3.4M
Return On Assets:
51.07%
Net Income Margin (TTM):
--
Return On Equity:
88.36%
Return On Invested Capital:
70.47%
Operating Margin:
-5698%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.6M | -- | $400K | -- | -- | |
| Gross Profit | $82K | -$3.8M | -$3.4M | -$722K | -$1.4M | |
| Operating Income | -$47M | -$60.7M | -$83.2M | -$15.3M | -$24M | |
| EBITDA | -$43.5M | -$56.9M | -$80M | -$14.6M | -$23.1M | |
| Diluted EPS | -$2.00 | -$2.70 | $1.17 | -$0.63 | -$0.10 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $67.9M | $25.5M | $57.3M | $112.7M | $216.1M | |
| Total Assets | $119M | $38.8M | $66.1M | $120.6M | $231.1M | |
| Current Liabilities | $26.5M | $12.6M | $8.4M | $18.4M | $22.2M | |
| Total Liabilities | $39.3M | $23.3M | $44M | $74.8M | $59.9M | |
| Total Equity | $79.7M | $15.4M | $22M | $45.8M | $171.2M | |
| Total Debt | $4.4M | $6.5M | $4M | $22.1M | $24M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.8M | -$48.8M | -$74.9M | -$12.2M | -$21.2M | |
| Cash From Investing | -$36.6M | -$46.6M | $114.4M | -$6.2M | -$64.6M | |
| Cash From Financing | $72.4M | $106.4M | $27.7M | -$299K | $5.2M | |
| Free Cash Flow | -$42.1M | -$50.7M | -$82.4M | -$12.6M | -$23.7M | |
ABEO
Sector
Market Cap
$263.9M
$28.8M
Price % of 52-Week High
64.59%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-10.18%
-1.32%
1-Year Price Total Return
-18.97%
-20.64%
Beta (5-Year)
1.120
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$4.83
200-day SMA
Sell
Level
$5.67
Bollinger Bands (100)
Sell
Level
4.86 - 6.66
Chaikin Money Flow
Sell
Level
-51.9M
20-day SMA
Buy
Level
$4.56
Relative Strength Index (RSI14)
Buy
Level
51.91
ADX Line
Buy
Level
19.7
Williams %R
Neutral
Level
-29.703
50-day SMA
Sell
Level
$4.99
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
21.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.1187)
Sell
CA Score
(Annual)
Level (-4.5467)
Buy
Beneish M-Score
(Annual)
Level (-5.3207)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4329)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Stock Forecast FAQ
In the current month, ABEO has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABEO average analyst price target in the past 3 months is $20.64.
-
Where Will Abeona Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Abeona Therapeutics, Inc. share price will rise to $20.64 per share over the next 12 months.
-
What Do Analysts Say About Abeona Therapeutics, Inc.?
Analysts are divided on their view about Abeona Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abeona Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Abeona Therapeutics, Inc.'s Price Target?
The price target for Abeona Therapeutics, Inc. over the next 1-year time period is forecast to be $20.64 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ABEO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Abeona Therapeutics, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ABEO?
You can purchase shares of Abeona Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abeona Therapeutics, Inc. shares.
-
What Is The Abeona Therapeutics, Inc. Share Price Today?
Abeona Therapeutics, Inc. was last trading at $4.87 per share. This represents the most recent stock quote for Abeona Therapeutics, Inc.. Yesterday, Abeona Therapeutics, Inc. closed at $4.87 per share.
-
How To Buy Abeona Therapeutics, Inc. Stock Online?
In order to purchase Abeona Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ABEO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ABEO
Sector
P/E ratio
4.18x
23.71x
PEG ratio
--
-0.01x
P/B ratio
1.54x
1.84x
Price / LTM sales
658.38x
1.60x
Growth Metrics
ABEO
Sector
Revenue growth
--
4.85%
Earnings growth
84.88%
11.15%
Revenue (5-year growth)
3.15%
6.45%
Earnings forecast
-$0.34
-$0.20
Profitability
ABEO
Sector
Profitability FY 2024
-$2.9M
$3.6M
Return on invested capital
70.47%
-30.98%
Return on assets
51.07%
-27.62%
Return on equity
88.36%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
17
Estimated Next Earnings Date
Feb
11
Balance Sheet
ABEO
Sector
Total cash
$207.5M
$27.2M
Short term investments
$74.4M
$25.7M
Total assets
$108.9M
$79.7M
Long term debt
$24M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
